Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

PURPOSE: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast Cancer Res Treat
Hauptverfasser: Campbell, Jeffrey I., Yau, Christina, Krass, Polina, Moore, Dan, Carey, Lisa A., Au, Alfred, Chhieng, David, Giri, Dilip, Livasy, Chad, Mies, Carolyn, Rabban, Joseph, Sarode, Venetia R., Singh, Baljit, Esserman, Laura, Chen, Yunn-Yi
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5653207/
https://ncbi.nlm.nih.gov/pubmed/28577078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4303-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge